Predict your next investment

Asset/Investment Management

See what CB Insights has to offer

Investments

15

Portfolio Exits

5

About Veron International

Veron International is a Hong Kong based investment firm that is part of the estate of Nina Wang (deceased). Veron International does not appear to be making investments any longer.

Veron International Headquarter Location

Hong Kong

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Veron International News

Veron International Ltd Declares Ownership of Stake in ConforMIS Inc (CFMS)

Mar 18, 2016

Tweet Veron International Ltd revealed that they own a 7.2% stake in ConforMIS Inc (NASDAQ:CFMS) in a Form 13G disclosure that was filed with the SEC on Thursday, March 17th. The investor owns 2,942,177 shares of the stock worth $26,626,702. The reporting parties listed on the disclosure included Veron International Ltd, Milestone Management Limited (“Milestone”), Kam Por Chan (“Chan) and Sunny Kwong Yeung (“Yeung”). The filing is available through Edgar at this link . Other hedge funds and other institutional investors also recently bought and sold shares of the company. RS Investment Management Co. LLC raised its position in ConforMIS by 3.1% in the fourth quarter. RS Investment Management Co. LLC now owns 1,432,470 shares of the company’s stock valued at $24,767,000 after buying an additional 43,490 shares during the period. Deutsche Bank AG raised its position in ConforMIS by 831.9% in the fourth quarter. Deutsche Bank AG now owns 73,183 shares of the company’s stock valued at $1,263,000 after buying an additional 65,330 shares during the period. Wells Fargo & Company MN raised its position in ConforMIS by 38.7% in the fourth quarter. Wells Fargo & Company MN now owns 501,056 shares of the company’s stock valued at $8,663,000 after buying an additional 139,708 shares during the period. Pier Capital LLC bought a new position in ConforMIS during the fourth quarter valued at $3,871,000. Finally, Stanhope Investments bought a new position in ConforMIS during the fourth quarter valued at $27,015,000. Shares of ConforMIS Inc ( NASDAQ:CFMS ) traded down 1.10% on Thursday, reaching $9.02. The company’s stock had a trading volume of 260,846 shares. ConforMIS Inc has a 52-week low of $7.55 and a 52-week high of $26.93. The firm’s 50 day moving average is $9.59 and its 200-day moving average is $15.95. The stock’s market cap is $370.81 million. ConforMIS (NASDAQ:CFMS) last posted its earnings results on Thursday, February 11th. The company reported ($0.37) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.04. During the same quarter in the prior year, the business earned ($2.83) EPS. The company earned $19.10 million during the quarter, compared to the consensus estimate of $17.23 million. The firm’s revenue for the quarter was up 34.5% compared to the same quarter last year. On average, equities research analysts forecast that ConforMIS Inc will post ($1.36) EPS for the current year. Several research firms have weighed in on CFMS. JPMorgan Chase & Co. set a $23.00 price target on ConforMIS and gave the stock an “overweight” rating in a research report on Monday, January 4th. Canaccord Genuity reaffirmed a “buy” rating and set a $26.00 price target (up previously from $22.00) on shares of ConforMIS in a research report on Tuesday, December 8th. Zacks Investment Research lowered ConforMIS from a “hold” rating to a “sell” rating in a report on Thursday, November 26th. Sterne Agee CRT started coverage on ConforMIS in a report on Tuesday, December 1st. They set a “buy” rating and a $26.00 target price on the stock. Finally, Deutsche Bank reissued a “buy” rating on shares of ConforMIS in a report on Monday, February 8th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $23.80. ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, to fit each patient’s anatomy. It is engaged in offering a line of customized knee implants designed to restore the natural shape of a patient’s knee. This story was originally published by American Banking News (http://www.americanbankingnews.com) and is the sole property of American Banking News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.americanbankingnews.com/2016/03/17/veron-international-ltd-declares-ownership-of-stake-in-conformis-inc-cfms/ Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here) . Receive News & Ratings for ConforMIS Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc and related companies with MarketBeat.com's FREE daily email newsletter . Leave a Reply

Veron International Investments

15 Investments

Veron International has made 15 investments. Their latest investment was in Chestnut Medical Technologies as part of their Series C on March 3, 2008.

CBI Logo

Veron International Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/21/2008

Series C

Chestnut Medical Technologies

$7.8M

Yes

7/5/2004

Series E

Pepgen

$7.5M

Yes

4/20/2004

Series C

BioForm Medical

$13M

Yes

10/20/2000

Unattributed VC - III

Subscribe to see more

$99M

Subscribe to see more

0

2/14/2000

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

0

Date

3/21/2008

7/5/2004

4/20/2004

10/20/2000

2/14/2000

Round

Series C

Series E

Series C

Unattributed VC - III

Unattributed VC

Company

Chestnut Medical Technologies

Pepgen

BioForm Medical

Subscribe to see more

Subscribe to see more

Amount

$7.8M

$7.5M

$13M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

0

0

Veron International Portfolio Exits

5 Portfolio Exits

Veron International has 5 portfolio exits. Their latest portfolio exit was BioForm Medical on November 07, 2007.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/7/2007

IPO

$99M

5/22/2006

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

5/18/2004

IPO

Subscribe to see more

Subscribe to see more

0

3/9/2001

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

3/24/2000

IPO

Subscribe to see more

$99M

Subscribe to see more

0

Date

11/7/2007

5/22/2006

5/18/2004

3/9/2001

3/24/2000

Exit

IPO

Acquired

IPO

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

0

0

0

0

Veron International Team

1 Team Member

Veron International has 1 team member, including current President, Nina Wang.

Name

Work History

Title

Status

Nina Wang

President

Current

Name

Nina Wang

Work History

Title

President

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.